Genetic risk factors associated with lipid-lowering drug-induced myopathies-Reference-Cited by-同舟云学术

Genetic risk factors associated with lipid-lowering drug-induced myopathies

Published:2006 Issue:2 Volume:34 Page:153-162
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Vladutiu Georgirene D.,Simmons Zachary,Isackson Paul J.,Tarnopolsky Mark,Peltier Wendy L.,Barboi Alexandru C.,Sripathi Naganand,Wortmann Robert L.,Phillips Paul S.

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Reference54 articles.

1. Clinical and Biochemical Aspects of Carnitine Deficiency and Insufficiency: Transport Defects and Inborn Errors of β-Oxidation

2. Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy

3. Molecular clues into the pathogenesis of statin-mediated muscle toxicity

4. The case of stainless statins

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statins in hereditary myopathies: to give or not to give;Neuromuscular Disorders;2024-08

2. Breaking down statin myopathy: understanding the self-limited and autoimmune subtypes;Rheumatology;2024-06-03

3. Incidence of statin-associated muscle symptoms in patients taking statins with RYR1 or CACNA1S variants;Personalized Medicine;2024-05-03

4. Statins as anti‐tumor agents: A paradigm for repurposed drugs;Cancer Reports;2024-05

5. Hydroxymethylglutaryl‐CoA reductase activity is essential for mitochondrial β‐oxidation of fatty acids to prevent lethal accumulation of long‐chain acylcarnitines in the mouse liver;British Journal of Pharmacology;2024-04-19